Effect of sulodexide on plasma transforming growth factor-beta1 in healthy volunteers.
It is unknown whether the glycosaminoglycan drug sulodexide interferes with transforming growth factor-beta1--a member of heparin-binding family and a potent regulator of human biology and diseases. Hence, a 2-week pilot study was performed in 11 healthy men. Sulodexide was initially administered intravenously in a single dose, then--orally for 12 days and--again intravenously on study completion. Initial injection had no effect on activated form of the growth factor measured in plasma after 10 and 120 min; no change was also observed after 120 min from drug ingestion on day 7. On final intravenous administration, the growth factor levels increased by almost 60% after 10 min and remained elevated; the 120-min levels directly correlated with sulodexide dosage. Baseline cytokine levels decreased during the 2-week trial by more than 50%. In conclusion, transforming growth factor-beta1 release and likely downregulation of its expression may constitute novel pharmacological effects of sulodexide.
Borawski
Jacek
J
Department of Nephrology and Transplantation with Dialysis Unit, Medical University, Bialystok, Poland. jborawski@post.pl
Dubowski
Miroslaw
M
Pawlak
Krystyna
K
Mysliwiec
Michal
M
D000284:Administration, Oral; D000328:Adult; D015536:Down-Regulation / Q000187:drug effects; D005343:Fibrinolytic Agents / Q000008:administration & dosage*; D006025:Glycosaminoglycans / Q000008:administration & dosage*; D006801:Humans; D007275:Injections, Intravenous; D008297:Male; D010865:Pilot Projects; D011446:Prospective Studies; D053773:Transforming Growth Factor beta1 / Q000097:blood*
D005343:Fibrinolytic Agents; D006025:Glycosaminoglycans; D053773:Transforming Growth Factor beta1; C007858:glucuronyl glucosamine glycan sulfate